The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis

Ebina, Kosuke; Hashimoto, Jun; Kashii, Masafumi; Hirao, Makoto; Kaneshiro, Shoichi; Noguchi, Takaaki; Tsukamoto, Yasunori; Yoshikawa, Hideki

doi:https://doi.org/10.1007/s00774-015-0731-x

The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis

Ebina, Kosuke; Hashimoto, Jun; Kashii, Masafumi et al.

Journal of Bone and Mineral Metabolism, 2017, 35(1), 91-98

アクセス数:970件（2025-07-17 13:58 集計）

固定URL: https://hdl.handle.net/11094/93257

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
JBoneMinerMetab_35_1_91	pdf	なし	676 KB	66	2023.12.07

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis
著者	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 著者名 Ebina, Kosuke
	NRID 1000040237938 1000040237938 著者名 Hashimoto, Jun
	NRID 1000000576910 1000000576910 著者名 Kashii, Masafumi
	NRID 1000010527708 1000010527708 著者名 Hirao, Makoto
	著者名 Kaneshiro, Shoichi
	NRID 1000050812294 1000050812294 researchmap permalink takaakinoguchi takaakinoguchi ORCID 0000-0001-9938-6780 0000-0001-9938-6780 著者名 Noguchi, Takaaki
	著者名 Tsukamoto, Yasunori
	NRID 1000060191558 1000060191558 著者名 Yoshikawa, Hideki
キーワード等	Daily teriparatide
	Denosumab
	Oral bisphosphonates
	Primary osteoporosis
内容	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00774-015-0731-x
内容	Ebina K., Hashimoto J., Kashii M., et al. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. Journal of Bone and Mineral Metabolism 35, 91 (2017); https://doi.org/10.1007/s00774-015-0731-x.
抄録	The aim of this 12-month, observational study was to compare the effects of switching daily teriparatide (TPTD) to oral bisphosphonates (BP) therapy or denosumab (DMAb) therapy in patients with primary osteoporosis. Patients [n = 78; 71 postmenopausal women and seven men; mean age 76.3 (64–94) years; mean duration of prior daily TPTD therapy 20.1 (6–24) months] were allocated to either the (1) “switch-to-BP” group [n = 36; weekly alendronate 35 mg (n = 19), weekly risedronate 17.5 mg (n = 12), monthly minodronate 50 mg (n = 5)]; or (2) “switch-to-DMAb” group (n = 42; 60 mg sc every 6 months) based on each physicians’ decision. Changes in bone mineral density (BMD) and serum bone turnover markers were monitored every 6 months. No significant difference was observed in baseline clinical characteristics between the groups. After 12 months, the increase in BMD was significantly greater in the switch-to-DMAb group compared to the switch-to-BP group: lumbar spine (6.2 vs. 2.6 %; P < 0.01), total hip (4.2 vs. 1.1 %; P < 0.05), and femoral neck (3.5 vs. 1.4 %; P < 0.05). In addition, the patients in the switch-to-DMAb group showed a significant decrease compared to those in the switch-to-BP group in TRACP-5b (−55.8 vs. −32.8 %; P < 0.01) and ucOC (−85.5 vs. −65.0 %; P < 0.001), while no significant difference was observed in PINP (−67.5 vs. −62.1 %). Switching daily TPTD to DMAb significantly increased BMD and decreased bone resorption marker compared to switching to oral BP at 12 months, and thus may provide an effective sequential treatment option after daily TPTD treatment.
出版者	Springer Nature
収録物名	Journal of Bone and Mineral Metabolism
巻(号)	35(1)
ページ	91-98
刊行年月	2017-01-01
言語	英語
ハンドルURL	https://hdl.handle.net/11094/93257
PISSN	09148779
eISSN	14355604
関連情報 (isVersionOf)	DOI (出版社版) https://doi.org/10.1007/s00774-015-0731-x
アクセス権	open access
出版タイプ	Accepted Manuscript
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Journal of Bone and Mineral Metabolism. 2017, 35(1), p. 91-98
DC.title	The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis
DC.creator	Ebina, Kosuke
	Hashimoto, Jun
	Kashii, Masafumi
	Hirao, Makoto
	Kaneshiro, Shoichi
	Noguchi, Takaaki
	Tsukamoto, Yasunori
	Yoshikawa, Hideki
DC.publisher	Springer Nature
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2017-01-01
DC.identifier	https://doi.org/10.1007/s00774-015-0731-x
DC.subject	Daily teriparatide
	Denosumab
	Oral bisphosphonates
	Primary osteoporosis
DC.description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00774-015-0731-x
DC.description	Ebina K., Hashimoto J., Kashii M., et al. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. Journal of Bone and Mineral Metabolism 35, 91 (2017); https://doi.org/10.1007/s00774-015-0731-x.
DCTERMS.abstract	The aim of this 12-month, observational study was to compare the effects of switching daily teriparatide (TPTD) to oral bisphosphonates (BP) therapy or denosumab (DMAb) therapy in patients with primary osteoporosis. Patients [n = 78; 71 postmenopausal women and seven men; mean age 76.3 (64–94) years; mean duration of prior daily TPTD therapy 20.1 (6–24) months] were allocated to either the (1) “switch-to-BP” group [n = 36; weekly alendronate 35 mg (n = 19), weekly risedronate 17.5 mg (n = 12), monthly minodronate 50 mg (n = 5)]; or (2) “switch-to-DMAb” group (n = 42; 60 mg sc every 6 months) based on each physicians’ decision. Changes in bone mineral density (BMD) and serum bone turnover markers were monitored every 6 months. No significant difference was observed in baseline clinical characteristics between the groups. After 12 months, the increase in BMD was significantly greater in the switch-to-DMAb group compared to the switch-to-BP group: lumbar spine (6.2 vs. 2.6 %; P < 0.01), total hip (4.2 vs. 1.1 %; P < 0.05), and femoral neck (3.5 vs. 1.4 %; P < 0.05). In addition, the patients in the switch-to-DMAb group showed a significant decrease compared to those in the switch-to-BP group in TRACP-5b (−55.8 vs. −32.8 %; P < 0.01) and ucOC (−85.5 vs. −65.0 %; P < 0.001), while no significant difference was observed in PINP (−67.5 vs. −62.1 %). Switching daily TPTD to DMAb significantly increased BMD and decreased bone resorption marker compared to switching to oral BP at 12 months, and thus may provide an effective sequential treatment option after daily TPTD treatment.
DC.format	93257
citation_title	The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis
citation_author	Ebina, Kosuke
	Hashimoto, Jun
	Kashii, Masafumi
	Hirao, Makoto
	Kaneshiro, Shoichi
	Noguchi, Takaaki
	Tsukamoto, Yasunori
	Yoshikawa, Hideki
citation_publisher	Springer Nature
citation_language	英語
citation_date	2017-01-01
citation_journal_title	Journal of Bone and Mineral Metabolism
citation_volume	35
citation_issue	1
citation_firstpage	91
citation_lastpage	98
citation_doi	https://doi.org/10.1007/s00774-015-0731-x
citation_public_url	https://hdl.handle.net/11094/93257

The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis

閲覧可能ファイル

論文情報

論文詳細を表示